Newsroom

KANSAS CITY, Mo.--(BUSINESS WIRE)--Commerce Bancshares, Inc. (NASDAQ: CBSH) announced today that it has participated in an exchange offer initiated by Visa Inc. (“Visa”) involving a portion of the Company’s Visa Class B‑2 common stock holdings. Under the terms of the exchange offer, and subject to final settlement, Commerce expects to exchange tendered Visa Class B‑2 shares for a combination of Visa Class B-3 common stock and Visa Class C common stock. The Company has tendered all 411,723 of it...

CAMBRIDGE, Engeland--(BUSINESS WIRE)--  Mundipharma kondigt positieve resultaten aan van de Fase III ReSPECT-studie waarin ▼ REZZAYO® (rezafungin) wordt geëvalueerd voor de profylaxe van invasieve schimmelziekten bij patiënten die een allogene hematopoëtische stamceltransplantatie ondergaan   Mundipharma heeft vandaag positieve resultaten bekendgemaakt van de wereldwijde klinische Fase III ReSPECT-studie waarin REZZAYO® (rezafunginacetaat) wordt geëvalueerd voor de profylaxe van invasieve schim...

NEW YORK--(BUSINESS WIRE)--Jamie Dimon, Chairman and Chief Executive Officer of JPMorganChase, will present at the Bernstein Strategic Decisions Conference in New York City on Wednesday, May 27, 2026, at 9:00 a.m. (Eastern). A live audio webcast will be available on the day of the conference at www.jpmorganchase.com under Investor Relations, Events & Presentations. JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with...

JASPER, Ind.--(BUSINESS WIRE)--German American Bancorp, Inc. (Nasdaq: GABC) (“German American” or the “Company”) announced financial results for the three months ended March 31, 2026. The Company also announced that its Board of Directors declared a regular quarterly cash dividend of $0.31 per share, which will be payable on May 20, 2026 to shareholders of record as of May 10, 2026. As previously reported, this dividend rate represents a 7% increase over the rate in effect during 2025. For the...

MCLEAN, Va.--(BUSINESS WIRE)--Booz Allen (NYSE: BAH) announced senior leadership appointments that strengthen the company’s position as an advanced technology provider....

ケンブリッジ（英国）--(BUSINESS WIRE)--（ビジネスワイヤ） -- ムンディファーマは、同種造血幹細胞移植（HSCT）を受ける成人患者における侵襲性真菌症（IFD）の予防を目的とした REZZAYO® （レザフンギン酢酸塩）を評価するためのグローバル臨床試験ReSPECTの第III相試験の良好な結果を発表しました。 ReSPECT第III相試験は、同種造血幹細胞移植を受ける成人におけるカンジダ、アスペルギルス、ニューモシスチスによる感染症を含む侵襲性真菌症の予防について、週1回投与のレザフンギンとSARの有効性および安全性を比較・評価する最大規模の抗真菌薬に関する多施設共同無作為化二重盲検試験の1つです。同種造血幹細胞移植を受ける患者は、長期間の免疫抑制に直面し、通常、長期の抗真菌予防投与が必要となります。1これは、投与量の差別化、副作用プロファイルの改善、薬物相互作用の低減が有益であり、同等の有効性が期待される状況となっています。 ReSPECT試験は、米国食品医薬品局（FDA）および欧州医薬品庁（EMA）の基準を満たす90日目の真菌フリー生存率という主要評価項目を...

OMAHA, Neb.--(BUSINESS WIRE)--Valmont® Industries, Inc. (NYSE: VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today announced that its Board of Directors has declared a quarterly dividend of $0.77 per share payable on July 15, 2026, to shareholders of record on June 26, 2026. The dividend indicates an annual rate of $3.08 per share. About Valmont Industries, Inc. For more than 80 years, Valmont has been a global...

Venlo, Niederlande--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die vorläufigen Ergebnisse für das erste Quartal 2026 bekannt gegeben. Das Unternehmen verzeichnete weiterhin eine starke Profitabilität mit einem bereinigten verwässerten Gewinn je Aktie, der den Erwartungen entsprach. Die Umsatzentwicklung war gemischt, wobei geringere Umsätze bei QuantiFERON und eine zurückhaltende Nachfrage seitens der US-Kunden im Bereich Life Sciences das solide Wachstum...

COLUMBIA, Md.--(BUSINESS WIRE)--COPT Defense Properties (“COPT Defense” or the “Company”) (NYSE: CDP) announced results for the first quarter ended March 31, 2026. Management Comments Stephen E. Budorick, COPT Defense’s President & Chief Executive Officer, commented, “We achieved solid results in the first quarter and our performance is tracking on all aspects of our full year plan. FFO per share exceeded the midpoint of our guidance range by $0.01. Based on this outperformance, and our for...

CAMBRIDGE, Großbritannien--(BUSINESS WIRE)--Mundipharma veröffentlichte heute positive Topline-Ergebnisse aus der globalen klinischen Phase-III-Studie ReSPECT, in der REZZAYO® (Rezafunginacetat) zur Prophylaxe invasiver Pilzerkrankungen (IFDs) bei erwachsenen Patienten untersucht wurde, die eine allogene hämatopoetische Stammzelltransplantation (HSCT) erhalten. Die ReSPECT-Phase-III-Studie ist eine der größten multizentrischen, randomisierten Doppelblindstudien im Bereich der Antimykotika und u...